SCHEMBL1597345

SCHEMBL1597345

c1ccc2nc(NC[C@@H]3CCCCN3)ncc2c1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP1A2 P05177 1/20 0.50
CYP3A4 P08684 1/20 0.50
CYP2D6 P10635 1/20 0.50
CYP2C9 P11712 1/20 0.50
CYP2C19 P33261 1/20 0.50
SYK P43405 3/20 0.48
KCNH2 Q12809 3/20 0.48
IRAK4 Q9NWZ3 3/20 0.45
POLB P06746 1/20 0.44
MAPK3 P27361 1/20 0.44
MAPK1 P28482 1/20 0.44
AURKB Q96GD4 1/20 0.44
CHEK1 O14757 1/20 0.42
FDPS P14324 1/20 0.40
PCSK9 Q8NBP7 1/20 0.40
CDK4 P11802 1/20 0.40
IDO1 P14902 2/20 0.40
TDO2 P48775 2/20 0.40
PRMT5 O14744 1/20 0.40
LTA4H P09960 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27873796 0.80 APP (0.49) IRAK4FDPSPCSK9
SCHEMBL1597743 0.79 CYP1A2 (0.59) CYP1A2CYP3A4CYP2D6CYP2C9CYP2C19
SCHEMBL1596888 0.79 CYP1A2 (0.59) CYP1A2CYP3A4CYP2D6CYP2C9CYP2C19
SCHEMBL1597909 0.78 IRAK4 (0.48) CYP1A2CYP3A4CYP2D6CYP2C9CYP2C19
SCHEMBL1596808 0.76 IDO1 (0.44) CYP1A2CYP2D6CYP2C19SYKKCNH2
SCHEMBL27136976 0.75 LTA4H (0.51) CYP1A2CYP3A4CYP2D6CYP2C9CYP2C19
SCHEMBL1598635 0.75 IDO1 (0.53) SYKKCNH2IRAK4MAPK3MAPK1
SCHEMBL1598637 0.75 IDO1 (0.53) SYKKCNH2IRAK4MAPK3MAPK1
Hydrochloric Acid SCHEMBL6817582 0.74 IDO1 (0.52) SYKKCNH2IRAK4MAPK3MAPK1
Hydrochloric Acid SCHEMBL6817578 0.74 IDO1 (0.52) SYKKCNH2IRAK4MAPK3MAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7919507-B2 N-aroyl cyclic amines SMITHKLINE BEECHAM LIMITED (GB) 2011-04-05 US disclosed
US-7741329-B2 N-aroyl cyclic amines SMITHKLINE BEECHAM LIMITED (GB) 2010-06-22 US disclosed
US-20090093478-A1 N-AROYL CYCLIC AMINES SMITHKLINE BEECHAM P.I.C. 2009-04-09 US disclosed
US-20090029986-A1 N-AROYL CYCLIC AMINES SMITHKLINE BEECHAM P.L.C. 2009-01-29 US disclosed
US-20090012073-A1 N-AROYL CYCLIC AMINES SMITHKLINE BEECHAM P.L.C. 2009-01-08 US disclosed
US-7432270-B2 N-aroyl cyclic amines SMITHKLINE BEECHAM P.L.C. (GB) 2008-10-07 US disclosed
EP-1956020-A2 1-[2-(heterocyclyl-aminomethyl)-piperidin-1-YL]-1-(2-methyl-5-phenyl-heterocyclyl)-methanone derivatives and related compounds as orexin-1 antagonists for the treatment of obesity SMITHKLINE BEECHAM PLC (GB) 2008-08-13 EP disclosed
EP-1385845-B1 N-AROYL CYCLIC AMINES SMITHKLINE BEECHAM PLC (GB) 2008-01-09 EP disclosed
US-20040143115-A1 N-aroyl cyclic amines SMITHKLINE BEECHAM LIMITED (GB) 2004-07-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090012073-A1 N-AROYL CYCLIC AMINES AANAT, MAOA, MAOB CYP1A2 31/4885CYP3A4 78/4885CYP2D6 32/4885
US-20090093478-A1 N-AROYL CYCLIC AMINES AANAT, MAOA, MAOB CYP1A2 31/4885CYP3A4 78/4885CYP2D6 32/4885
US-20090029986-A1 N-AROYL CYCLIC AMINES AANAT, MAOA, MAOB CYP1A2 31/4885CYP3A4 78/4885CYP2D6 32/4885
US-20040143115-A1 N-aroyl cyclic amines HCRTR1, HCRTR2, CNR1 CYP1A2 512/4885CYP3A4 735/4885CYP2D6 789/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.